Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Moat Score: 0/10 (As of Jul. 07, 2026)


CAI:RMDA Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents CAI:RMDA
84 GF Score
Price E£5.10
GF Value E£4.08
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Moat Score?

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents might have No Moat - No discernible moat.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents  (CAI:RMDA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Moat Score Related Terms

CAI:RMDA
84GF Score
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents CAI:RMDA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Overvalued in 2026?

Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock appears to be overvalued. The current stock price of E£5.10 is trading 25% above its estimated GF Value™ of E£4.08. GuruFocus considers Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents to be Modestly Overvalued.

Key valuation signals for CAI:RMDA:

  • Moat Score: 0
  • GF Value™: E£4.08 vs. price of E£5.10 (25% above fair value)
  • GF Score™: 84/100 with 9 warning signs

No single metric tells the full story. See the CAI:RMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Business Description

Address No. 5 Second Industrial Zone, Sixth of October City, Giza, EGY
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use; manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals; importing pharmaceutical reagents and raw materials necessary for serving the its purposes without trading; producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others; and producing food supplements for human use for others and by others. It has two segments: production and selling of pharmaceutical products, which generates maximum revenue; and manufacturing for others (Toll manufacturing).
84GF Score

Get the complete analysis for CAI:RMDA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£5.10
Price
E£4.08
GF Value